SOMAPACITAN

Information current as at: 1 June 2026

No activity by the pharmaceutical company has been recorded for this medicine for six(6) months. The process for listing is considered inactive.

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Sogroya®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: Novo Nordisk Pharmaceuticals Pty. Limited
Condition/indication: (therapeutic use): Adult growth hormone deficiency
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: New listing (–)
Comment:: --
Other PBAC consideration:: --

Submission received for:: March 2022 PBAC meeting
Opportunity for consumer comment:: Open 24/11/2021 and close 27/01/2022 (see PBS Website)
PBAC meeting:: Held on 09/03/2022
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: 11/04/2022
Lodgement of required documentation:: 20/04/2022
Acceptance of complete documentation:: Accepted
6Agreement to listing arrangements:: Commenced on 28/04/2022
Status:: Under consideration
7Government processes:: Has not yet commenced
8Medicine listed on the PBS:: Has not yet occurred

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

Case ID

a502

Page last updated

31 March 2026

v.9.19